Today’s Stock On Watch: Could Sophiris Bio Inc Crash Even More? The Stock Had Another Big Decline Today

Today's Stock On Watch: Could Sophiris Bio Inc Crash Even More? The Stock Had Another Big Decline Today

The stock of Sophiris Bio Inc (NASDAQ:SPHS) is a huge mover today! About 592,666 shares traded hands. Sophiris Bio Inc (NASDAQ:SPHS) has risen 106.62% since April 14, 2016 and is uptrending. It has outperformed by 101.93% the S&P500.
The move comes after 8 months negative chart setup for the $84.60 million company. It was reported on Nov, 16 by We have $2.35 PT which if reached, will make NASDAQ:SPHS worth $11.00M less.

Analysts await Sophiris Bio Inc (NASDAQ:SPHS) to report earnings on November, 21.

Sophiris Bio Inc (NASDAQ:SPHS) Ratings Coverage

Out of 3 analysts covering Sophiris Bio (NASDAQ:SPHS), 3 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Sophiris Bio has been the topic of 3 analyst reports since August 30, 2016 according to StockzIntelligence Inc. Roth Capital initiated Sophiris Bio Inc (NASDAQ:SPHS) rating on Thursday, September 15. Roth Capital has “Buy” rating and $8.0 price target. The stock of Sophiris Bio Inc (NASDAQ:SPHS) has “Buy” rating given on Thursday, September 15 by TH Capital. Piper Jaffray initiated it with “Overweight” rating and $7 target price in Tuesday, August 30 report.

According to Zacks Investment Research, “Sophiris Bio Inc. operates as a biopharmaceutical company. The Company is developing a treatment for benign prostatic hyperplasia (BPH or enlarged prostate). It has operations based in San Diego. Sophiris Bio Inc. is based in Canada.”

Insitutional Activity: The institutional sentiment decreased to 0.77 in Q2 2016. Its down 1.98, from 2.75 in 2016Q1. The ratio worsened, as 8 funds sold all Sophiris Bio Inc shares owned while 5 reduced positions. 5 funds bought stakes while 5 increased positions. They now own 1.50 million shares or 31.22% less from 2.18 million shares in 2016Q1.
Kcg Holding owns 17,013 shares or 0% of their US portfolio. Deutsche Bank & Trust Ag last reported 20,822 shares in the company. Morgan Stanley reported 225 shares or 0% of all its holdings. Creative Planning has 0% invested in the company for 900 shares. Fny Managed Accounts Limited Liability Company accumulated 0% or 7,556 shares. Royal Bancorp Of Canada reported 5,971 shares or 0% of all its holdings. Jane Street Grp Limited Liability Company holds 0% of its portfolio in Sophiris Bio Inc (NASDAQ:SPHS) for 27,176 shares. Wells Fargo And Mn has invested 0% of its portfolio in Sophiris Bio Inc (NASDAQ:SPHS). Airain Limited holds 0% of its portfolio in Sophiris Bio Inc (NASDAQ:SPHS) for 32,017 shares. Rock Springs Capital Mgmt Limited Partnership reported 490,000 shares or 0.08% of all its holdings. Fincl Bank Of Montreal Can accumulated 1,632 shares or 0% of the stock. Vanguard has 331,000 shares for 0% of their US portfolio. Ladenburg Thalmann Finance Svcs, a Florida-based fund reported 600 shares. The New York-based Bancshares Of Mellon has invested 0% in Sophiris Bio Inc (NASDAQ:SPHS). Citadel Limited Co has 49,176 shares for 0% of their US portfolio.

More notable recent Sophiris Bio Inc (NASDAQ:SPHS) news were published by: which released: “Sophiris Bio Reports Third Quarter 2016 Financial Results and Key Business …” on November 09, 2016, also with their article: “Sophiris Bio Inc. to Raise Approximately $5 Million Through At-the-Market Offering” published on May 06, 2016, published: “Sophiris Bio Prices Public Offering of Common Shares and Warrants” on August 23, 2016. More interesting news about Sophiris Bio Inc (NASDAQ:SPHS) were released by: and their article: “Sophiris Bio To Present Topsalysin Phase 3 Data from Positive PLUS-1 Study as …” published on May 05, 2016 as well as‘s news article titled: “Sophiris Bio Closes Underwritten Public Offering” with publication date: August 26, 2016.

SPHS Company Profile

Sophiris Bio Inc., incorporated on May 1, 2003, is a clinical-stage biopharmaceutical company. The Firm is focused on developing products for the treatment of urological diseases. The Firm is developing topsalysin (PRX302) as a treatment for the lower urinary tract symptoms of benign prostatic hyperplasia (BPH) commonly referred to as an enlarged prostate and as a treatment for localized low to intermediate risk prostate cancer.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment